In support of combinatorial treatment, multiple studies have reported enhancement of chemotherapy and/or rituximab sensitivity in lymphoma/leukemia cells and xenografts when combined with survivin inhibition [18, 39, 47, 59]. Here, BIRC5 is linked to lymphoma.